
Patritumab
CAS No. 1262787-83-6
Patritumab ( —— )
产品货号. M36726 CAS No. 1262787-83-6
Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用,可有效抑制 EGFR,HER2,HER3,ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis),也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥3837 | 有现货 |
![]() ![]() |
5MG | ¥6363 | 有现货 |
![]() ![]() |
10MG | ¥9932 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Patritumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用,可有效抑制 EGFR,HER2,HER3,ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis),也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。
-
产品描述Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
-
体外实验Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.:Western Blot Analysis Cell Line:DiFi-HRG cells Concentration:10 μg/mL Incubation Time:6 hours Result:Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.
-
体内实验Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)Dosage:1 mg/body Administration:Intraperitoneal injection; twice a week for 4 weeks Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
-
同义词——
-
通路MAPK/ERK Signaling
-
靶点ERK
-
受体ERK | EGFR | HER | Akt
-
研究领域——
-
适应症——
化学信息
-
CAS Number1262787-83-6
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56. ?